RENB
Income statement / Annual
Last year (2023), Renovaro Biosciences Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Renovaro Biosciences Inc.'s net income was -$80.65 M.
See Renovaro Biosciences Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$42,769.00
|
| Cost of Revenue |
$121,859.00 |
$113,496.00 |
$123,590.00 |
$391,416.00 |
$366,269.00 |
$71,709.00 |
$18,484.00 |
$14,528.00 |
$32,669.00 |
| Gross Profit |
-$121,859.00 |
-$113,496.00 |
-$123,590.00 |
-$391,416.00 |
-$366,269.00 |
-$71,709.00 |
-$18,484.00 |
-$14,528.00 |
$10,100.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0.24 |
| Research and Development
Expenses |
$2.71 M
|
$4.17 M
|
$8.37 M
|
$15.72 M
|
$4.69 M
|
$2.50 M
|
$616,961.00
|
$62,763.00
|
$804,188.00
|
| General & Administrative
Expenses |
$24.56 M
|
$15.32 M
|
$14.33 M
|
$7.56 M
|
$7.12 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$383,549.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$24.56 M
|
$15.32 M
|
$14.33 M
|
$7.56 M
|
$7.12 M
|
$8.42 M
|
$2.60 M
|
$2.32 M
|
$1.33 M
|
| Other Expenses |
$54.37 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$81.64 M |
$19.60 M |
$22.83 M |
$23.40 M |
$11.92 M |
$10.92 M |
$3.22 M |
$2.39 M |
$2.13 M |
| Cost And Expenses |
$81.64 M |
$19.60 M |
$22.83 M |
$23.40 M |
$11.92 M |
$10.99 M |
$3.24 M |
$2.40 M |
$2.16 M |
| Interest Income |
$0.00 |
$0.00 |
$122,041.00 |
$13,179.00 |
$50,296.00 |
$73,487.00 |
$45,816.00 |
$0.00 |
$0.00 |
| Interest Expense |
$1.01 M |
$706,964.00 |
$372,844.00 |
$379,608.00 |
$104,280.00 |
$43.00 |
$143,262.00 |
$26,259.00 |
$2,364.00 |
| Depreciation &
Amortization |
$121,859.00
|
$113,496.00
|
$123,590.00
|
$123,534.00
|
$366,268.00
|
$71,709.00
|
$18,484.00
|
$14,528.00
|
$27,395.00
|
| EBITDA |
-$79.52 M
|
-$19.48 M
|
-$22.70 M
|
-$23.28 M
|
-$11.51 M
|
-$17.94 M
|
-$5.31 M
|
-$2.39 M
|
-$2.17 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-48.95 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-49.59
|
| Total Other
Income/Expenses Net |
$989,124.00
|
-$1.13 M
|
$2.65 M
|
-$3.45 M
|
$507,410.00
|
-$7.03 M
|
-$3.19 M
|
$192,720.00
|
-$77,096.00
|
| Income Before Tax |
-$80.65 M |
-$39.68 M |
-$113.43 M |
-$26.85 M |
-$11.42 M |
-$18.02 M |
-$6.42 M |
-$2.21 M |
-$2.20 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-51.39
|
| Income Tax Expense |
$0.00 |
$706,964.00 |
$34.00 |
-$125,276.00 |
$104,280.00 |
$1.00 |
-$111,716.00 |
-$64,877.00 |
-$462,787.00 |
| Net Income |
-$80.65 M |
-$39.68 M |
-$113.43 M |
-$26.72 M |
-$11.42 M |
-$18.02 M |
-$6.31 M |
-$2.14 M |
-$1.74 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-40.57 |
| EPS |
-0.84 |
-0.71 |
-2.16 |
-0.57 |
-0.25 |
-0.48 |
-0.29 |
-0.17 |
-0.18 |
| EPS Diluted |
-0.84 |
-0.71 |
-2.16 |
-0.57 |
-0.25 |
-0.48 |
-0.29 |
-0.17 |
-0.18 |
| Weighted Average Shares
Out |
$96.25 M
|
$56.27 M
|
$52.53 M
|
$47.17 M
|
$46.33 M
|
$37.55 M
|
$21.94 M
|
$12.27 M
|
$9.53 M
|
| Weighted Average Shares
Out Diluted |
$96.25 M
|
$56.27 M
|
$52.53 M
|
$47.17 M
|
$46.33 M
|
$37.55 M
|
$21.94 M
|
$12.27 M
|
$9.53 M
|
| Link |
|
|
|
|
|
|
|
|
|
